Literature DB >> 336379

Long term effect of timolol and hydrochlorothiazide, or hydrochlorothiazide and amiloride, in essential hypertension.

H Castenfors.   

Abstract

Twenty-four patients with mild to moderate hypertension were treated for up to 60 weeks with hydrochlorothiazide and either placebo, timolol, or timolol and amiloride. The effect of adding timolol and amiloride to hydrochlorothiazide was evaluated in a double blind trial. In 22 of the 24 patients a supine diastolic blood pressure below or equal to 95 mm Hg was produced by hydrochlorothiazide and timolol. Replacing a potassium supplement with amiloride increased the antihypertensive effect.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 336379     DOI: 10.1007/bf00645129

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Proceedings: "First-pass" effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man.

Authors:  C Bahr; G Alván; M Lind; B Mellström; V Sjöqvist
Journal:  Acta Pharm Suec       Date:  1974-12

2.  Plasma potassium determination.

Authors:  E HULTMAN; J BERGSTROM
Journal:  Scand J Clin Lab Invest       Date:  1962       Impact factor: 1.713

3.  Physiological disposition and metabolism of timolol in man and laboratory animals.

Authors:  D J Tocco; A E Duncan; F A Delauna; H B Hucker; V F Gruber; W J Vandenheuvel
Journal:  Drug Metab Dispos       Date:  1975 Sep-Oct       Impact factor: 3.922

4.  Renin-suppressive potency of various beta-adrenergic blocking agents at supine rest and during upright exercise.

Authors:  F R Bühler; G Marbet; U Patel; F Burkart
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06

5.  [The potassium retaining effect of Moduretic].

Authors:  R Henning; L Werkö
Journal:  Lakartidningen       Date:  1974-09-11

6.  The effect of different diuretics on elevated blood pressure and serum potassium.

Authors:  B Degnbol; S Dorph; T Marner
Journal:  Acta Med Scand       Date:  1973-05

7.  On the mechanism of suppressed plasma-renin activity during beta-adrenergic blockade with propranolol.

Authors:  E L Bravo; R C Tarazi; H P Dustan
Journal:  J Lab Clin Med       Date:  1974-01

8.  Evaluation of MK-870: a new potassium-sparing diuretic.

Authors:  B N Singh; D E Richmond; J D Wilson; H A Simmonds; J D North
Journal:  Br Med J       Date:  1967-01-21

9.  Propranolol in hypertension.

Authors:  B N Prichard; P M Gillam
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

10.  Treatment of hypertension with propranolol.

Authors:  B N Prichard; P M Gillam
Journal:  Br Med J       Date:  1969-01-04
View more
  6 in total

Review 1.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

2.  Individual factors influencing the response to a beta-adrenergic blocking agent given alone and in combination with a diuretic on arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

3.  Propranolol and beta-adrenergic receptor blocking drugs in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1982-01       Impact factor: 4.335

4.  Comparison of hydrochlorothiazide and atenolol as initial treatment in uncomplicated hypertension.

Authors:  E van der Veur; B S ten Berge; A J Donker; J F May; F H Schuurman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 5.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Fixed combination of sotalol and hydrochlorothiazide in the treatment of uncomplicated hypertension.

Authors:  A Jäättelä
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.